

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I CLINICAL TRIAL OF SYH2083 EYE DROPS FOR THE TREATMENT OF DRY EYE DISEASE OFFICIALLY INITIATED IN CHINA

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Phase I clinical trial (SYH2083-001) of SYH2083 eye drops (the “**Product**”), developed by the Group for the treatment of dry eye disease, has been officially initiated in China.

The Product is a dual-target inhibitor of lymphocyte function-associated antigen 1 (“**LFA-1**”) and reactive aldehyde species (“**RASP**”). It can inhibit the interaction between LFA-1 and intercellular adhesion molecule-1 (ICAM-1), reduce LFA-1-mediated cell adhesion, and efficiently capture RASP. The Product is expected to exert a synergistic effect through the dual targets of LFA-1 and RASP, addressing the limitations of single-target drugs in terms of safety and efficacy, thereby providing a potentially superior treatment option for patients with dry eye disease.

SYH2083-001 is a single-centre, randomised, double-blind, placebo-controlled and dose-escalation Phase I clinical trial conducted in healthy participants in China. It aims to evaluate the safety, tolerability and pharmacokinetic profile of the Product following single and multiple dose in healthy participants. Currently, the recruitment and screening of participants for this clinical trial are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 20 October 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.